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Kounis Syndrome Manifesting as Acute 
ST-Segment Elevation Due to Coronary 
Vasospasm After Cefuroxime-Induced 
Anaphylactic Shock
Nikolaos Laschos, MD, Stavros Tzerefos, MD, Andreas Katsaros, MD, 
Dimitrios Chrissos, MD
A B S T R A C T
A 41-year-old patient presented to the emergency room after intake of cefuroxime 
500 mg. He had dyspnea and hypotension and the electrocardiogram (ECG) showed 
ST-segment elevation in leads II, III, aVF, V2-V6. He was successfully managed with 
oxygen, intravenous corticoids, antihistamines and epinephrine. This constellation of 
presenting symptoms and signs was attributed to a manifestation of Kounis syndrome 
(allergic angina). The connection between acute coronary syndromes and anaphylaxis 
seems to be strong. The same mediators released during acute allergic reactions are 
increased in blood or urine of patients suffering from acute coronary syndromes of 
non allergic etiology.
I N T R O D U C T I O N
Cefuroxime is a second-generation cephalosporin antibiotic that has been widely 
available around the world for a long time (since 1977 in the USA). Cefuroxime is gener-
ally well tolerated and side effects are usually transient. Most common side-effects are 
diarrhea, nausea, vomiting, headaches, migraines, dizziness, and abdominal pain. There 
is a widely quoted cross allergy risk of 10% between cephalosporin and penicillin. In 
the medical literature, cefuroxime has been implicated as a cause of Kounis syndrome. 
Kounis syndrome is defined as the concurrence of acute coronary syndromes with 
conditions associated with mast cell activation involving interrelated and interacting 
inflammatory cells, and including allergic or hypersensitivity and anaphylactic insults.
C A S E  R E P O R T
A 41-year-old man was admitted to the emergency room (ER) of a General Hos-
pital in a state of shock. He had received a tablet of cefuroxime because of an upper 
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respiratory tract infection. He had no medical record of drug 
allergies. Five to ten minutes after taking the pill, he developed 
pruritus and a quickly expanded skin rash. He complained of 
dyspnea and dizziness. In the ER he presented with skin rash, 
weak pulmonary sounds on auscultation with prolonged expi-
ration, quiet heart sounds, regular heart rate at 70 beats per 
minute, and blood pressure of 85/45 mmHg. Complete blood 
count showed eosinophilia (7.4%), neutrophilia (82.6%), and 
no other abnormalities. Biochemical analysis showed mild hy-
perglycemia (glucose 8.9 mmol/l). Electrolytes, liver enzymes, 
creatine kinase, blood urea nitrogen, and creatinine were all 
normal. Troponin T was negative. Arterial blood gas analysis 
showed a pH of 7.35, pCO2 36 mmHg, pO2 62 mmHg, and 
oxygen saturation 90%. ECG revealed ST-segment elevation 
in leads II, III, aVF, and V2-V6 without ST-segment elevation 
in the right precordial leads (Fig. 1).
The patient was treated with oxygen via a Venturi mask 
providing a fraction of inspired oxygen of 35%, intravenous 
hydrocortisone (250 mg bolus dose) and an antihistamine 
agent (dimethindene maleate 4 mg intravenously). He was 
then transferred to the intensive care unit where he was placed 
on continuous monitoring. At 20 minutes after his admission, 
the ST-segment elevation was not present (Fig. 2). The patient 
developed dyspnea and wheezing, for which he received epi-
nephrine (1 mg subcutaneously) in order to maintain arterial O2 
saturation above 90%. His clinical condition improved quickly 
but treatment was continued with intravenous methylpredni-
solone 40 mg tid and per os cetirizine dihydrochloride 10 mg 
bid for three more days. Repeat ECG recordings showed a 
regular heart rhythm and a rate of 72 bpm with negative T-
wave in leads II, III, aVF, and V2-V6 three days after admission 
(Fig. 3). Troponin T reached 0.45 ng/ml the next day (normal 
<0.1 ng/ml) and became negative two days later. Electrolytes 
and creatine kinase (CK)-MB were within normal range. 
Echocardiography revealed no wall motion abnormalities (left 
ventricular ejection fraction 60-65%) with normal systolic and 
diastolic function. Measurements of specific IgE, histamine 
and tryptase serum levels were not performed. Patient was 
subsequently scheduled for coronary angiography and cardiac 
magnetic resonance (CMR) imaging. Coronary angiography 
did not show any severe obstructive atherosclerotic lesions, 
while CMR was negative for myocarditis.
D I S C U S S I O N
Acute coronary syndromes (ACS) are a serious clinical 
problem. The association between ACS and anaphylaxis 
seems to be strong. It has been shown that the same media-
tors released during acute allergic reactions are increased in 
blood or urine of patients suffering from ACS of non allergic 
etiology. Released mediators involved in Kounis syndrome 
are histamine, neutral proteases such as chymase and tryptase, 
platelet activating factor, cytokines, chemokines, arachidonic 
acid products, leukotriens and prostaglandins. These substances 
activate and interact with macrophages, T-lymphocytes and 
endothelial cells.1-3 Locally activated mast cells participate 
in the weakening of atherosclerotic plaques predisposing to 
FIgURE 1. Patient’s ECG at presentation in the emergency room.
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FIgURE 2. Patient’s ECG 20 minutes after initial treatment.
FIgURE 3. Patient’s ECG three days after admission.
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plaque erosion or rupture.4
There are three variants of Kounis syndrome. The type I 
variant includes patients with normal coronary arteries without 
predisposing factors for coronary artery disease, in whom the 
acute release of inflammatory mediators can induce either 
coronary artery spasm without increase of cardiac enzymes and 
troponins or coronary artery spasm progressing to acute myo-
cardial infarction with raised cardiac enzymes and troponins.
Type II variant includes patients with culprit but quiescent 
pre-existing athero matous disease, in whom the acute release 
of inflammatory mediators can induce either coronary artery 
spasm with normal cardiac enzymes and troponins or plaque 
erosion or rupture manifesting as acute myocardial infarction.
Type III variant includes patients with coronary artery 
thrombosis (including stent thrombosis), in whom aspirate 
thrombus specimens stained with hematoxylin-eosin and 
Giemsa demonstrate the presence of eosinophils and mast 
cells respectively.3,5
Several conditions are related to Kounis syndrome such as 
angioedema, bronchial asthma, food allergy, mastocytosis, se-
rum sickness, urticaria, Churg-Strauss syndrome, and idiopathic 
anaphylaxis. Allergens that trigger the release of mediators 
are antibiotics, analgesics, corticosteroids, antineoplastics, 
contrast media, anticoagulants, thrombolytics, stings (ants, 
bee wasp, and jellyfish), poison ivy, viper venom poisoning, 
and millet allergy.3
Apparently the presented case was type I Kounis syndrome. 
To our knowledge, in the literature there are four reports 
with Kounis syndrome after either per os or intramuscular 
administration of cefuroxime axetil.6-9 Kounis syndrome is 
reported in a wide range of ages, from 9 to 90 years old. Other 
antibiotics that have been implicated as causative agents of 
Kounis syndrome are listed in Table 1.
Involvement of the heart during an anaphylactic episode 
has been reported. It is generally believed that, during an al-
lergic reaction, systemic vasodilation, reduced venous return 
and leakage of plasma and volume loss due to increase in 
vascular permeability contribute to coronary hypoperfusion 
and myocardial damage. However, clinical and experimental 
evidence indicates that the heart can be the primary target 
of anaphylaxis. It was shown that within three minutes after 
antigen administration, the cardiac output decreased 90%, 
arterial blood pressure decreased 35%, and end-diastolic 
left ventricular pressure rose. Arterial blood pressure started 
declining four minutes after antigen administration. Rapid 
increase in end-diastolic pressure of left ventricle suggests 
that reduced venous return and volume loss are not the pri-
mary causes of documented depression in cardiac output and 
blood pressure.15,16 The presence of Kounis syndrome in intact 
coronary arteries is a strong argument that allergic mediators 
have a direct role in myocardial damage.16
Physicians have to be familiar with Kounis syndrome, 
otherwise the diagnosis is difficult. Patients have to be aware 
of any allergies and not only drug related. Allergy alert cards 
should be provided from health authorities. Drugs and natural 
molecules which stabilize mast cell membrane and monoclonal 
antibodies that protect mast cell surface could emerge as novel 
therapeutic modalities capable to prevent acute coronary and 
cerebrovascular events.
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Vancomycin14
38
HOSPITAL CHRONICLES 8(1), 2013
9. Mazarakis A, Koutsojannis CM, Kounis NG, Alexopoulos D. 
Cefuroxime-induced coronary artery spasm manifesting as 
Kounis syndrome. Acta Cardiol 2005; 60:341-345.
10. Kilic D, Evrengül H, Ozcan AV, Tanriverdi H, Caglıyan O, Kaf-
tan A. Acute ST segment elevation myocardial infarction after 
sulbactam-penicillin induced anaphylactic shock in an adult 
with significant coronary artery disease: a case report. Int J Car-
diol 2009; 135:e30-33.
11. Tigen K, Cevik C, Basaran y. Acute myocardial infarction 
following amoxicillin allergy: coronary angiography and ultra-
sound findings. Acta Cardiol 2007; 62:525-528.
12. Biteker M, Duran NE, Biteker FS, et al. Kounis syndrome sec-
ondary to amoxicillin/clavulanic acid use in a child. Int J Cardiol 
2009; 136:e3-5.
13. Almpanis G, Siahos S, Karogiannis NC, et al. Kounis syndrome: 
two extraordinary cases. Int J Cardiol 2011; 147:e35-38.
14. Lopez PR, Peiris AN. Kounis syndrome. South Med J 2010; 
103:1148-1155.
15. Felix SB, Baumann G, Berdel WE. Systemic anaphylaxis -- 
separation of cardiac reactions from respiratory and peripheral 
vascular events. Res Exp Med 1990; 190:239-252.
16. Fassio F, Almerigogna F. Kounis syndrome (allergic acute coro-
nary syndrome): different views in allergologic and cardiologic 
literature. Intern Emerg Med 2012; 7:489-495.
